Philippe Boileau,Nina Ting Qi,Mark J van der Laan et al.
Philippe Boileau et al.
An endeavor central to precision medicine is predictive biomarker discovery; they define patient subpopulations which stand to benefit most, or least, from a given treatment. The identification of these biomarkers is often the byproduct of ...
Randomized Controlled Trial
Biostatistics (Oxford, England). 2023 Oct 18;24(4):1085-1105. DOI:10.1093/biostatistics/kxac029 2023
Designing three-level cluster randomized trials to assess treatment effect heterogeneity [0.03%]
设计三层次集群随机试验以评估治疗效果异质性
Fan Li,Xinyuan Chen,Zizhong Tian et al.
Fan Li et al.
Cluster randomized trials often exhibit a three-level structure with participants nested in subclusters such as health care providers, and subclusters nested in clusters such as clinics. While the average treatment effect has been the prima...
Bayesian design of clinical trials using joint models for recurrent and terminating events [0.03%]
基于联合模型的临床试验贝叶斯设计方法研究复发和终止事件的问题
Jiawei Xu,Matthew A Psioda,Joseph G Ibrahim
Jiawei Xu
Joint models for recurrent event and terminating event data are increasingly used for the analysis of clinical trials. However, few methods have been proposed for designing clinical trials using these models. In this article, we develop a B...
Douglas R M Azevedo,Marcos O Prates,Dipankar Bandyopadhyay
Douglas R M Azevedo
The confounding between fixed effects and (spatial) random effects in a regression setup is termed spatial confounding. This topic continues to gain attention and has been studied extensively in recent years, given that failure to account f...
Peter B Gilbert,Youyi Fong,Avi Kenny et al.
Peter B Gilbert et al.
An immune correlate of risk (CoR) is an immunologic biomarker in vaccine recipients associated with an infectious disease clinical endpoint. An immune correlate of protection (CoP) is a CoR that can be used to reliably predict vaccine effic...
Denis Agniel,Boris P Hejblum,Rodolphe Thiébaut et al.
Denis Agniel et al.
When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of efficacy may be expensive to collect, not routinely available, or may take a long time to occur. In these cases, it is sometimes possible to i...
Randomized Controlled Trial
Biostatistics (Oxford, England). 2023 Oct 18;24(4):985-999. DOI:10.1093/biostatistics/kxac020 2023
Pierre Masselot,Fateh Chebana,Céline Campagna et al.
Pierre Masselot et al.
In environmental epidemiology, there is wide interest in creating and using comprehensive indices that can summarize information from different environmental exposures while retaining strong predictive power on a target health outcome. In t...
A hierarchical prior for generalized linear models based on predictions for the mean response [0.03%]
基于平均响应预测的广义线性模型的层次先验
Ethan M Alt,Matthew A Psioda,Joseph G Ibrahim
Ethan M Alt
There has been increased interest in using prior information in statistical analyses. For example, in rare diseases, it can be difficult to establish treatment efficacy based solely on data from a prospective study due to low sample sizes. ...
A probabilistic gene expression barcode for annotation of cell types from single-cell RNA-seq data [0.03%]
基于单细胞RNA测序数据的细胞类型注释的概率基因表达条形码
Isabella N Grabski,Rafael A Irizarry
Isabella N Grabski
Single-cell RNA sequencing (scRNA-seq) quantifies gene expression for individual cells in a sample, which allows distinct cell-type populations to be identified and characterized. An important step in many scRNA-seq analysis pipelines is th...
Reformulating provider profiling by grouping providers treating similar patients prior to evaluating performance [0.03%]
先分类再评价：改革供给方评级体系以减少偏差性评分的影响
Gabriella C Silva,Roee Gutman
Gabriella C Silva
Standard approaches to comparing health providers' performance rely on hierarchical logistic regression models that adjust for patient characteristics at admission. Estimates from these models may be misleading when providers treat differen...